alexa CTC Immune Escape Mediated By PD-L1
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Breast Cancer
May 08-10, 2017 Singapore

Wang Xuefei
Peking Union Medical College Hospital, China
Keynote: Breast Can Curr Res
DOI: 10.4172/2572-4118-C1-001
Breast cancer is the most common malignant tumor in women around the world. CTC (circulating tumor cell) is associated with the breast cancer patients’ cancer-related deaths and prognosis. The recently circulating clusters were found and its metastasis and tumor formation ability is 23~50 times as CTC. However, its mechanism has not been clarified. These days, researchers have successfully completed CTC cluster separation, CTC cell culture, and PD-L1 was found to be related with histological grading of tumor. Meanwhile, the high expression of PD-L1 in CTC surface has also been reported. Since PDL1 can mediate Treg to play the role of immunosuppression, we propose that CTC with positive PD-L1 is easier to connect PD-L1, immune cells and CK cytokines etc. Treg cells can protect CTC from being attacked by the immune system through the immunosuppression. Meanwhile, they can weaken CTL killing ability and trigger more MDSC. Finally, CTC formed the metastasis. To explore this hypothesis we have analyzed CTC and PD-L1 mRNA expression on CTC in 10 metastatic breast cancer patients and 10 primary breast cancer patients. We have also analyzed the relationship between clinical pathological features and PD-L1 expression on CTC, through overall and split chi square test. The results show that in the total 20 patients, 15 have more than 1 CTC in 7.5 ml peripheral blood. Among the 15 patients, each one has at least 1 CTC showing PD-L1. We found PD-L1 on CTC is related to the tumor size (P=0.012) lymph node status (P=0.001) and PR status (P=0.037). In tumor size group, we can see statistical difference between T2 and T3 (P=0.003), while in node status group statistical difference can be found in N1 vs. N3 (P=0.000) and N2 vs. N3 (P=0.015). However, we didn’t see difference of PD-L1 on CTC in metastatic and non-metastatic patients (P=0.418). Next, we are preparing for the cell experiment to further discover it.

Wang Xuefei is a Medicine Doctor graduated from PUMCH (Peking Union Medical College and Hospital). Currently, she is the fellow of the breast surgery department in PUMCH. She is also a member of Beijing Breast Disease Society of Young Academic. These years, her researches are focused on metastatic breast cancer, especially on CTC of breast cancer. She has also obtained the patent of CTC hemodialysis, meanwhile, participated in a number of national projects, including Beijing Municipal Science and Technology project, National 11th Five-Year issue, National 12th Five-Year issue. She has published more than 14 articles and books, including 4 SCI articles, and did oral and poster presentation in many breast cancer related conferences.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version